Rofecoxib: clinical pharmacology and clinical experience

Weaver, Arthur L.

doi:10.1016/s0149-2918(01)80112-0

Cited by 54 publications

(18 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…53,[112][113][114][115][116][117][118][119][120][121][122][123][124][125][126][127][128][129][130] Two foreign language systematic reviews were not included due to difficulties in obtaining the references within the project time frame. 131,132 Three aspects of these reviews were assessed in detail:…”

Section: Current Use Of Nsaidsmentioning

confidence: 99%

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

Chen

Jobanputra²,

Barton³

et al. 2008

Health Technol Assess

271

174

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: P Jobanputra has received funding from Pfizer for two research studies: 'quality of care in patients with musculoskeletal pain who use NSAIDs' and 'perception of risk in relation to NSAID use for patients with RA and OA'. He has also been entertained, paid to speak and provided with financial assistance for educational purposes by many manufacturers of non-steroidal anti-inflammatory drugs, new and old. RS Taylor has undertaken paid presentations for Pfizer (Canada) and Novartis (UK) not related to rheumatoid arthritis or osteoarthritis management. HTA Published April 2008This report should be referenced as follows:Chen Y-F, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in th...

show abstract

Section: Current Use Of Nsaidsmentioning

confidence: 99%

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

Chen

Jobanputra²,

Barton³

et al. 2008

Health Technol Assess

271

174

View full text Add to dashboard Cite

show abstract

“…Inhibition of the COX-2 isoform limits the synthesis of inflammatory and algesic mediators as may be released during tissue injury and thereby provides effective analgesia. 1,5,[9][10][11][12][13][20][21][22] However, nonselective NSAIDs have not been uniformly embraced as perioperative analgesics, primarily because of potentially undesirable binding to the COX-1 isoform. Inhibition of this isoform prevents such constitutive physiologic functions as generation of thromboxane (for vasoconstriction and platelet-derived hemostasis) and maintenance of gastrointestinal mucosal integrity.…”

Section: Objectifmentioning

confidence: 99%

“…teers and nonsurgical patients have indicated that COX-2 inhibitors have virtually no effect on the gastric mucosa or platelet function. [1][2][3][4] Safety in the perioperative setting has been suggested by the lack of increased intraoperative blood loss in patients receiving this class of drug. 5,6 Despite these favourable findings, many clinicians remain hesitant to administer COX-2 inhibitors perioperatively until there is more definitive evidence that these drugs do not alter platelet function during anesthesia and surgery.…”

mentioning

confidence: 99%

Rofecoxib does not compromise platelet aggregation during anesthesia and surgery

Silverman

Halaszynski

Sinatra

et al. 2003

Can J Anesth/J Can Anesth

View full text Add to dashboard Cite

show abstract

“…It has been approved for primary dysmenorrhea, acute pain after dental and orthopedic surgery, fever, and pain and inflammation in osteoarthritis and rheumatoid arthritis. 3 In clinical trials, gastrointestinal toxicity, including mucosal damage, perforation, ulcers and bleeding, occurred significantly less often with rofecoxib than ibuprofen, naproxen or diclofenac. 3 It does not affect bleeding time and platelet aggregation, but has no advantage in terms of renal toxicity.…”

Section: The First-generation Cox-2 Inhibitorsmentioning

confidence: 99%

Cyclooxygenase-2 Inhibitors in Gynecologic Practice

Connolly¹

2003

Clinical Medicine & Research

View full text Add to dashboard Cite

Treatment of pain and inflammation associated with dysmenorrhea, endometriosis, ovarian cancers and operative procedures is an ongoing challenge in gynecology. Understanding the roles of prostanoids and estrogen in these conditions and appropriate treatment approaches have advanced beyond traditional nonsteroidal anti-inflammatory drugs. In this article, the author describes some of the basic mechanisms of nonspecific nonsteroidal anti-inflammatory drugs and newer cyclooxygenase-2 inhibitors, especially as they are used in the obstetrics/gynecology practice.

show abstract

Rofecoxib: clinical pharmacology and clinical experience

Cited by 54 publications

References 25 publications

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

Rofecoxib does not compromise platelet aggregation during anesthesia and surgery

Cyclooxygenase-2 Inhibitors in Gynecologic Practice

Contact Info

Product

Resources

About